Vaxinano slider1

Innovation

for

Human and Animal Health

Protection

Home

Vaxinano specializes in the development of prophylactic and therapeutic vaccines for infectious diseases, for human and animal health markets.

We develop safe-by-design, more stable and efficient, adjuvant- and needle-free vaccines. Our patented technology centers on the use of bioavailable and bioeliminable nanoparticles.

Vaxinano is an R&D biotech aiming to bring potential vaccines to market in partnership with the pharmaceutical sector. We develop proofs-of-concept for new vaccines and can improve existing ones. Our experimental vaccines target toxoplasmosis and tuberculosis, and we are developing anti-bacterial, anti-viral and anti-parasitic vaccines.

In addition to vaccine development, we perform contract research and assist our customers in their nanomedicine R&D. Vaxinano can work with you towards a solution for your vaccine projects, and we welcome the challenge of meeting your needs.

Our academic partners :

VAXINANO is a start-up accomapnied by Eurasanté, and localized at the medicine faculty of the University of Lille2, inside the Lille Inflammation Research International Center (LIRIC-UMR 995) in partnership with INSERM and CHRU Lille.



Logo